Boehringer to Settle Lawsuits for $650 Million

German drugmaker Boehringer Ingelheim has said it will pay about $650 million to settle US lawsuits that claimed the company's blockbuster blood thinner, Pradaxa (dabigatran) caused severe and fatal bleeding.

Boehringer said it expected to resolve about 4,000 claims with the settlement. The claimants had accused the company of not issuing sufficient warnings of the risks associated with the drug.

While the company denied liability, it said the deal would allow it to avoid the distraction and uncertainty of a lengthy litigation process.

A lawyer for the plaintiffs said he was hopeful that claimants would receive compensation within a year as lawyers move to implement the settlement. The amount each individual receives will vary depending on the severity and nature of the alleged injury.

On the US market since 2008 - since 2010 in the US - Pradaxa is one of a new class of blood thinners used in stroke prevention and is designed to replace the widely used generic drug warfarin, which requires extensive blood testing.

The drug, which competes with Bayer and Johnson & Johnson's Xarelto as well as Bristol Myers-Squibb Co and Pfizer's Eliquis, had annual sales of about €1.2 billion in 2013.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.